Technical Outlook And Game Plan For PDS Biotechnology Corporation (NASDAQ: PDSB)

0
188

Renaissance Technologies LLC has recently announced that it has increased stake in PDS Biotechnology Corporation (NASDAQ:PDSB) by 101.11%. After grabbing 0.62 million shares, the institutional investor is now in possession of 0.31 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 4.05% having worth around $2.28 million. Moreover, Geode Capital Management LLC increased its share by 65773.0 to have a control over 83909.0 shares. And Two Sigma Advisers LP raised its holdings to 32800.0 shares by acquiring 32800.0 shares or 0.21% of the stake.

PDS Biotechnology Corporation (PDSB) concluded trading on 08/27/20 at a closing price of $2.37, with 1.37 million shares of worth about $3.24 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -18.84% during that period and on Thursday the price saw a loss of about -13.19%. Currently the company’s common shares owned by public are about 15.36M shares, out of which, 10.75M shares are available for trading.

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the PDSB stock and their offered price forecasts bring an average price target of $8.25. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $10.00 and could fall to a lowest price of $6.50. Analysts also issued an outlook of 2.20 for the PDS Biotechnology Corporation stock for next 12 months. However, touching the estimated high of $10.00 would mean a gain of 76.3% for the stock.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 4 times over the past 12 months. They bought 499,815 shares in 4 of the transactions. In 0 selling transactions, insiders dumped 0 shares.

Federated Hermes Kaufmann Fund, Fidelity Extended Market Index Fu, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in PDS Biotechnology Corporation Federated Hermes Kaufmann Fund is currently holding 0.38 million shares of worth totaling $1.37 million. The company recently came buying 0.0 shares which brought its stake up to 2.44% of the company’s outstanding shares. Vanguard Extended Market Index Fu, after buying 31726.0 shares, have now control over 0.21% of the stake in the company. It holds 17019.0 shares of worth $0.12 million.

PDS Biotechnology Corporation (NASDAQ: PDSB) started trading at $2.72, below -$0.01 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $2.37, or with a loss of -13.19%. Stock saw a price change of -18.84% in past 5 days and over the past one month there was a price change of -33.98%. Year-to-date (YTD), PDSB shares are showing a performance of -10.57% which decreased to -57.30% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.62 but also hit the highest price of $6.16 during that period. While comparing its average daily trading volume of 1.93 million shares, we see that about 1.37 million changed hands on the day. The stock is currently trading -29.30% below its 20-day simple moving average (SMA20), while that difference is down -14.44% for SMA50 and it goes to 22.87% higher than SMA200.

Renaissance Technologies LLC acquired 0.62 million shares of PDS Biotechnology Corporation having value of about $2.28 million. Data submitted at the U.S SEC by Renaissance Technologies LLC revealed that the firm now holds 0.31 million shares in the company valued at close to $741930.87, or have control over 101.11% stake in the company. PDS Biotechnology Corporation (NASDAQ: PDSB) currently have 15.36M outstanding shares and institutions hold larger chunk of about 8.00% of that. Holding of mutual funds in the company is about 3.36% while other institutional holders and individual stake holders have control over 6.04% and 13.73% of the stake respectively.

The stock has a current market capitalization of $50.05M and its 3Y-monthly beta is at 3.17. It has posted earnings per share of -$2.46 in the same period. It has Quick Ratio of 7.70 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PDSB, volatility over the week remained 10.43% while standing at 10.28% over the month.

Analysts are in expectations that PDS Biotechnology Corporation (PDSB) stock would likely to be making an EPS of -$0.2 in the current quarter, while forecast for next quarter ESPS is -$0.19 and it is $0.11 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.27 which is -$0.14 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$1.1 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 94.50% while it is estimated to increase by 100.90% in next year.

Analysts at 2 brokerage firms have issued recommendations for the PDS Biotechnology Corporation (PDSB)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.20. Out of those 2 Wall Street analysts, 2 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Alliance Global Partners on May 27, 2020 offering a Buy rating for the stock and assigned a target price of $4 to it. Coverage by Noble Capital Markets stated PDS Biotechnology Corporation (PDSB) stock as an Outperform in their note to investors on March 09, 2020, suggesting a price target of $5.45 for the stock.

LEAVE A REPLY

Please enter your comment!
Please enter your name here